Form 4: Caribou Biosciences CMO Granted Equity, Sells for Tax

Caribou Biosciences' Chief Medical Officer, Tina M. Albertson, received grants of restricted stock units and stock options, alongside a non-discretionary sale of shares to cover tax obligations.

Summary

• Chief Medical Officer Tina M. Albertson acquired 55,000 Restricted Stock Units (RSUs) on February 20, 2026, at a price of $0.
• These RSUs are scheduled to vest in four equal annual installments, commencing on February 20, 2027, contingent on continued service.
• Albertson also received an option to purchase 247,500 shares of Common Stock on February 20, 2026, with an exercise price of $1.80.
• This option vests monthly, with 1/48 of the total shares vesting on each monthly anniversary of the grant date, leading to full vesting by February 20, 2030, subject to continued service.
• A "sell-to-cover" transaction occurred on February 24, 2026, involving the sale of 1,066 shares of Common Stock at $1.96 per share.
• This sale was solely to satisfy tax withholding obligations related to the vesting of previously granted RSUs and was executed under a Rule 10b5-1 trading plan adopted on August 12, 2024.
• Following these transactions, Albertson beneficially owns 68,523 shares of Common Stock and options to purchase 247,500 shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive compensation practices that align management's long-term interests with shareholder value, without indicating any immediate operational or financial shifts.

Positives

• Chief Medical Officer Tina M. Albertson received significant equity grants, including 55,000 Restricted Stock Units and options to purchase 247,500 shares, aligning her interests with long-term shareholder value and company performance.

Negatives

• No direct negatives identified; the reported sale of 1,066 shares was a non-discretionary "sell-to-cover" transaction for tax withholding, not a discretionary sale indicating a lack of confidence.

Future Outlook

The filing details future vesting schedules for the granted Restricted Stock Units, which begin on February 20, 2027, and for the stock options, which will be fully vested by February 20, 2030, contingent on continued service to the Issuer.

Industry Context

StockSavvy.ai notes that the grants of restricted stock units and stock options to a Chief Medical Officer are a common practice in the biotechnology and pharmaceutical industries to attract, retain, and incentivize key talent, aligning executive performance with long-term company growth and shareholder interests. The "sell-to-cover" transaction is also a routine event for executives to manage tax liabilities associated with equity vesting.

Comparison to Industry Standards

• The equity grants to the Chief Medical Officer are consistent with compensation structures observed across the biotechnology sector, where companies like Moderna (MRNA) and BioNTech (BNTX) frequently use similar RSU and option grants to incentivize their executive teams.
• The "sell-to-cover" transaction for tax obligations is a standard mechanism for executives across all industries, including tech giants like Apple (AAPL) and pharmaceutical leaders like Pfizer (PFE), to manage tax liabilities arising from vested equity awards without engaging in discretionary market sales.

Stakeholder Impact

• Shareholders: The equity grants align the Chief Medical Officer's financial incentives with the long-term performance of Caribou Biosciences, potentially fostering greater commitment to company growth and value creation.

Next Steps

• The 55,000 Restricted Stock Units will vest in four equal annual installments beginning February 20, 2027.
• The option to purchase 247,500 shares will vest monthly over four years, fully vesting by February 20, 2030.

Key Dates

Recommendation

This Form 4 filing primarily details routine executive compensation through equity grants and a non-discretionary tax-related stock sale. While the grants align management's interests with shareholders, these are standard events and do not provide new fundamental information to warrant a change in investment thesis. Therefore, a "hold" recommendation is appropriate as the filing does not present new catalysts for significant price movement.

Keywords

Caribou Biosciences, CRBU, Form 4, insider trading, stock options, restricted stock units, executive compensation, Tina M. Albertson, Chief Medical Officer, equity grant, sell-to-cover, Rule 10b5-1